Now showing items 1-8 of 8
Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG Phase 2 randomized clinical trial
(American Medical Association, 2020)
Importance: Because of socioeconomic factors, many patients with advanced non-small cell lung cancer (NSCLC) do not receive immunotherapy in the first-line setting. It is unknown if the combination of immunotherapy with ...
Squamous cell lung cancer: genomic evolution and personalized therapy
(Instituto Nacional de Salud Pública, 2019)
Objetivo. Revisar el estado del arte en relación con la información actual sobre el cáncer de pulmón de células escamosas (CPCE) y describir las anomalías genéticas reportadas, su efecto y los agentes terapéuticos más ...
Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab
(International Institute of Anticancer Research, 2017)
Background: Heavily treated patients with nonsmall cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total ...
An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)
Background A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies ...
Lung cancer disparities in hispanics: molecular diagnosis and use of immunotherapy
(American Society of Clinical Oncology, 2020-06-01)